Featured Posts
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing. That…
Blog
The unseen costs of banning PBM-owned pharmacies in Tennessee
Tennessee lawmakers recently passed the FAIR Rx Act, which would bar companies from owning pharmacies while also operating a pharmacy benefit manager (PBM) and…
Blog
FDA’s Moderna decision demonstrates how science and government are incompatible
Last week, the FDA announced that it would not be considering Moderna’s application for a new flu vaccine because the control group Moderna used…
Search Posts
News Release
Senate Big Beautiful Bill Contains Needed Medicaid Reforms
The Senate today voted 51 to 50 to pass the Reconciliation package known as the “One Big Beautiful Bill,” following House passage in May.
Blog
FDA can’t stomach fluoride and doesn’t want you to, either
On May 13, the Food and Drug Administration (FDA) announced that it would begin a process intended to exclude ingestible prescription fluoride products for…
Blog
The MAHA Report is a missed opportunity
Less than six months into the new administration, the Department of Health and Human Services (HHS) has produced its Make Our Children Healthy Again…
Blog
CBO likely overestimates effects of Medicaid reforms
Yesterday, the Congressional Budget Office (CBO) released its estimates of the costs, both financial and in coverage, of the One Big Beautiful Bill Act…
News Release
MAHA Commission recommendations on improving government-directed research merit consideration
President Trump’s Make America Healthy Again Commission released the “Making Our Children Health Again” report, which seeks to evaluate health trends among America’s youth,…
The Washington Examiner
Capping drug prices will cripple innovation and harm public health
The Washington Examiner cited CEI’s expert on life-saving drugs and technology The Competitive Enterprise Institute was similarly scathing. “As with many industries, the United States…